Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Non-Current Deffered Revenue (2016 - 2025)

Sangamo Therapeutics (SGMO) has 14 years of Non-Current Deffered Revenue data on record, last reported at $5.9 million in Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue changed N/A year-over-year to $5.9 million; the TTM value through Sep 2025 reached $5.9 million, changed N/A, while the annual FY2024 figure was $5.9 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $5.9 million in Q3 2025 per SGMO's latest filing, roughly flat from $5.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $222.3 million in Q1 2021 and bottomed at $1.8 million in Q1 2023.
  • Average Non-Current Deffered Revenue over 5 years is $100.4 million, with a median of $115.6 million recorded in 2022.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 195.29% in 2021, then tumbled 98.79% in 2023.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $166.8 million in 2021, then crashed by 34.42% to $109.4 million in 2022, then tumbled by 98.34% to $1.8 million in 2023, then surged by 223.46% to $5.9 million in 2024, then changed by 0.0% to $5.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $5.9 million in Q3 2025, $5.9 million in Q2 2025, and $5.9 million in Q1 2025.